https://impact.ornl.gov/en/publications/sup225supac-macropatate-a-novel-a-particle-peptide-receptor-radio/
225Ac-MACROPATATE: A Novel a-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine...
a novelradionuclide therapyparticle
https://pmc.ncbi.nlm.nih.gov/articles/PMC12388893/
Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance...
Targeted alpha therapy (TAT) has recently emerged as a highly promising approach for the management of metastatic castration-resistant prostate cancer (mCRPC),...
targeted alpha therapy
https://impact.ornl.gov/en/publications/rearmed-bifunctional-chelating-ligand-for-sup225supacsup155suptb-/
Rearmed Bifunctional Chelating Ligand for 225Ac/155Tb Precision-Guided Theranostic...
bifunctionalchelatingprecisionguided
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1516860/full
Frontiers | The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate...
BackgroundWe aimed to report our clinical experience with the use of 225Ac-PSMA-617 in the treatment of mCRPC patients.MethodsA retrospective analysis was co...
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-225ac-psma-trillium-for-prostate-cancer-that-has-spread-pantha
A study looking at 225Ac-PSMA-Trillium for prostate cancer that has spread (PAnTHA)
This study is looking at 225Ac-PSMA-Trillium for people with prostate cancer that has spread to another part of the body and is getting worse.